News of Note—Merck petition, GeoVax partnership and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> A petition challenging Merck's decision to phase out a RotaTeq supply deal for four African countries has generated nearly 50,000 signatures. Petition | FiercePharma article

> GeoVax signed a partnership with Virometix to develop a therapeutic HPV vaccine. Release

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

> Initial data for NantKwest's cancer vaccine left analysts confused about the candidate's potential benefit. FierceBiotech article

> ImmusanT started a phase 2 study for its celiac disease vaccine. Release (PDF)

> With support from the Gates Foundation, InDevR will apply its VaxArray potency testing platform to measles and rubella vaccines. Release

Read more on

Suggested Articles

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.